RGLS REGULUS THERAPEUTICS INC Operational Disruptions 8-K Filing 2024 - Phase 1b Study Results Regulus Therapeutics announced positive results from its Phase 1b study of RGLS8429 for the treatment of ADPKD, showing dose response and reductions in kidney size.Get access to all SEC 8-K filings of the REGULUS THERAPEUTICS INC